Drug intelligence / Profile preview

iHSC002

Development stage: Preclinical
Lead developer: Cell Inspire Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

iHSC002 is a preclinical-stage cell therapy developed by Cell Inspire Biotechnology. It consists of hematopoietic stem cells (HSCs) derived from induced pluripotent stem cells (iPSCs) that have been genetically engineered to secrete Interleukin-15 (IL-15). The primary objective of this modification is to enhance the development of lymphoid lineages, such as T cells and Natural Killer (NK) cells, and to support overall immune function. By utilizing an iPSC-based platform, iHSC002 aims to provide a scalable and potentially off-the-shelf source of functional hematopoietic stem cells for the treatment of hematological malignancies and other immune-related disorders.

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on iHSC002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iHSC002.

Explore the full profile